These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

417 related items for PubMed ID: 23813665

  • 1. Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression.
    Cunill R, Castells X, Tobias A, Capellà D.
    Pharmacoepidemiol Drug Saf; 2013 Sep; 22(9):961-9. PubMed ID: 23813665
    [Abstract] [Full Text] [Related]

  • 2. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
    Stuhec M, Munda B, Svab V, Locatelli I.
    J Affect Disord; 2015 Jun 01; 178():149-59. PubMed ID: 25813457
    [Abstract] [Full Text] [Related]

  • 3. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP, Keating GM.
    Paediatr Drugs; 2009 Jun 01; 11(3):203-26. PubMed ID: 19445548
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.
    Adler LA, Spencer T, Brown TE, Holdnack J, Saylor K, Schuh K, Trzepacz PT, Williams DW, Kelsey D.
    J Clin Psychopharmacol; 2009 Feb 01; 29(1):44-50. PubMed ID: 19142107
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.
    Cheng JY, Chen RY, Ko JS, Ng EM.
    Psychopharmacology (Berl); 2007 Oct 01; 194(2):197-209. PubMed ID: 17572882
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of atomoxetine hydrochloride in Korean adults with attention-deficit hyperactivity disorder.
    Lee SI, Song DH, Shin DW, Kim JH, Lee YS, Hwang JW, Park TW, Yook KH, Lee JI, Bahn GH, Hirata Y, Goto T, Takita Y, Takahashi M, Lee S, Treuer T.
    Asia Pac Psychiatry; 2014 Dec 01; 6(4):386-96. PubMed ID: 25345739
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression.
    Schwartz S, Correll CU.
    J Am Acad Child Adolesc Psychiatry; 2014 Feb 01; 53(2):174-87. PubMed ID: 24472252
    [Abstract] [Full Text] [Related]

  • 9. [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].
    Purper-Ouakil D, Fourneret P, Wohl M, Rénéric JP.
    Encephale; 2005 Feb 01; 31(3):337-48. PubMed ID: 16142049
    [Abstract] [Full Text] [Related]

  • 10. A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability.
    Treuer T, Gau SS, Méndez L, Montgomery W, Monk JA, Altin M, Wu S, Lin CC, Dueñas HJ.
    J Child Adolesc Psychopharmacol; 2013 Apr 01; 23(3):179-93. PubMed ID: 23560600
    [Abstract] [Full Text] [Related]

  • 11. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.
    Simpson D, Plosker GL.
    CNS Drugs; 2004 Apr 01; 18(6):397-401. PubMed ID: 15089111
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
    Adler LA, Wilens T, Zhang S, Dittmann RW, D'Souza DN, Schuh L, Durell TM.
    Clin Ther; 2012 Feb 01; 34(2):363-73. PubMed ID: 22285724
    [Abstract] [Full Text] [Related]

  • 15. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
    Harfterkamp M, van de Loo-Neus G, Minderaa RB, van der Gaag RJ, Escobar R, Schacht A, Pamulapati S, Buitelaar JK, Hoekstra PJ.
    J Am Acad Child Adolesc Psychiatry; 2012 Jul 01; 51(7):733-41. PubMed ID: 22721596
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS, Setyawan J, Zimovetz EA, Hodgkins P.
    Curr Med Res Opin; 2014 Aug 01; 30(8):1673-85. PubMed ID: 24627974
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Open-label, dose-titration tolerability study of atomoxetine hydrochloride in Korean, Chinese, and Taiwanese adults with attention-deficit/hyperactivity disorder.
    Takahashi M, Goto T, Takita Y, Chung SK, Wang Y, Gau SS.
    Asia Pac Psychiatry; 2014 Mar 01; 6(1):62-70. PubMed ID: 23857916
    [Abstract] [Full Text] [Related]

  • 20. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun 01; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.